{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:46Z","timestamp":1777289086732,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00393-019-0645-4","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T03:22:53Z","timestamp":1557804173000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biologikabehandlung bei der juvenilen idiopathischen Arthritis","Biologics in the treatment of juvenile idiopathic arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"Ariane","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"issue":"3","key":"645_CR1","first-page":"622","volume":"29","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric Rheumatologists. (2002) Health care provision in pediatric rheumatology in Germany\u2014National rheumatologic database. J\u00a0Rheumatol 29(3):622\u2013628","journal-title":"J Rheumatol"},{"key":"645_CR2","first-page":"1377","volume":"33","author":"S Danner","year":"2006","unstructured":"Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M et\u00a0al (2006) Epidemiology of juvenile idiopathic arthritis in Alsace, France. J\u00a0Rheumatol 33:1377\u20131381","journal-title":"J Rheumatol"},{"issue":"4","key":"645_CR3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG et\u00a0al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465\u2013482","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"645_CR4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","volume":"142","author":"G Dueckers","year":"2012","unstructured":"Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176\u2013193","journal-title":"Clin Immunol"},{"issue":"4","key":"645_CR5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10067-015-2861-x","volume":"34","author":"T Witte","year":"2015","unstructured":"Witte T (2015) Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol 34(4):629\u2013634","journal-title":"Clin Rheumatol"},{"issue":"9410","key":"645_CR6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Mart\u00edn Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363(9410):675\u2013681","journal-title":"Lancet"},{"issue":"1","key":"645_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","volume":"74","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Conaghan PG, Martin-Mola E et al (2014) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74(1):35\u201343","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"645_CR8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG et al (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: The ACT-RAY study. Ann Rheum Dis 73(5):803\u2013809","journal-title":"Ann Rheum Dis"},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-12-102","volume":"12","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Buckley F, Dejonckheere F, Ogale S (2014) Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs\u2014A systematic review and network meta-analysis. Health Qual Life Outcomes 12:102. \nhttps:\/\/doi.org\/10.1186\/1477-7525-12-102","journal-title":"Health Qual Life Outcomes"},{"key":"645_CR10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I et\u00a0al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis 68:519\u2013525","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"645_CR11","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","volume":"67","author":"R Davies","year":"2015","unstructured":"Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (2015) Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. arthritis Rheumatol 67(9):2487\u20132494","journal-title":"arthritis Rheumatol"},{"issue":"2","key":"645_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/03009742.2018.1488182","volume":"48","author":"A Klein","year":"2019","unstructured":"Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G (2019) Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: Long-term data from the German BIKER registry. Scand J Rheumatol 48(2):95\u2013104. \nhttps:\/\/doi.org\/10.1080\/03009742.2018.1488182","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"645_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J et\u00a0al (2016) Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 18(1):272. \nhttps:\/\/doi.org\/10.1186\/s13075-016-1170-3","journal-title":"Arthritis Res Ther"},{"key":"645_CR14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","volume":"75","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Niewerth M, Haas J et al (2016) Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 75:855\u2013861","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"645_CR15","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"EH Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60(9):2794\u20132804","journal-title":"Arthritis Rheum"},{"issue":"4","key":"645_CR16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, TEMPO Study Investigators (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54(4):1063\u20131074","journal-title":"Arthritis Rheum"},{"issue":"1","key":"645_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26\u201337","journal-title":"Arthritis Rheum"},{"key":"645_CR18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K et\u00a0al (2008b) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N\u00a0Engl J Med 359:810\u2013820","journal-title":"N Engl J Med"},{"key":"645_CR19","volume-title":"Safety of adalimumab ADA \u00b1 methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (pJIA): STRIVE registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4)","author":"H Brunner","year":"2017","unstructured":"Brunner H, Ruperto N, Nanda K, Toth M, Foeldvari I, Bohnsack JF, Milojevic D, Rabinovich CE, Kingsbury D, Marzan K, Quartier P, Minden K, Chalom E, Horneff G, Kuester RM, Dare JA, Bereswill M, Kalabic J, Kupper H, Lovell DJ, Martini A et\u00a0al (2017) Safety of adalimumab ADA \u00b1 methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (pJIA): STRIVE registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). \nhttp:\/\/acrabstracts.org\/abstract\/safety-of-adalimumabADA-%c2%b1-methotrexate-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-pjia-strive-registry\/\n\n. Zugegriffen: 4. Mai 2017"},{"issue":"11","key":"645_CR20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/acr.22072","volume":"65","author":"P Emery","year":"2013","unstructured":"Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC (2013) Golimumab, human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1\u2011year and 2\u2011year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken) 65(11):1732\u20131742","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"645_CR21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I et al (2016) Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: Five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken) 68(6):744\u2013752","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9685","key":"645_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landew\u00e9 R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210\u2013221 (Erratum in Lancet 2009; 374(9699):1422)","journal-title":"Lancet"},{"issue":"1","key":"645_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2017","unstructured":"Brunner HI, Ruperto N, Tzaribachev N et al (2017) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a\u00a0multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 77(1):21\u201329","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"645_CR24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2014","unstructured":"Brunner HI, Ruperto N, Zuber Z et al (2014) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a\u00a0phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110\u20131117","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"645_CR25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","volume":"65","author":"P Nash","year":"2013","unstructured":"Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M (2013) Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: Results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) 65(5):718\u2013728","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"645_CR26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","volume":"74","author":"KA van Schie","year":"2015","unstructured":"van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74(1):311\u2013314","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"645_CR27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","volume":"44","author":"A Skrabl-Baumgartner","year":"2015","unstructured":"Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J (2015) Anti-adalimumab antibodies in juvenile idiopathic arthritis: Frequent association with loss of response. Scand J Rheumatol 44(5):359\u2013362","journal-title":"Scand J Rheumatol"},{"key":"645_CR28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S et al (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 50:1445\u20131452","journal-title":"Rheumatology"},{"issue":"12","key":"645_CR29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947\u20131955","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"645_CR30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2013","unstructured":"Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H (2013) The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 53(2):213\u2013222","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"645_CR31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J et al (2017) Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs 31(4):299\u2013316","journal-title":"BioDrugs"},{"issue":"1","key":"645_CR32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","volume":"84","author":"J Sigaux","year":"2017","unstructured":"Sigaux J, Hamze M, Daien C, Morel J, Krzysiek R, Pallardy M, Maillere B, Mariette X, Miceli-Richard C (2017) Immunogenicity of tocilizumab in patients with rheumatoid arthritis. Joint Bone Spine 84(1):39\u201345","journal-title":"Joint Bone Spine"},{"issue":"4","key":"645_CR33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3899\/jrheum.150430","volume":"43","author":"T Constantin","year":"2016","unstructured":"Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I et al (2016) Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J\u00a0Rheumatol 43(4):816\u2013812. \nhttps:\/\/doi.org\/10.3899\/jrheum.150430","journal-title":"J Rheumatol"},{"issue":"11","key":"645_CR34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N\u00a0Engl J Med 342(11):763\u2013769","journal-title":"N Engl J Med"},{"issue":"1","key":"645_CR35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","volume":"50","author":"TR Southwood","year":"2011","unstructured":"Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, Hull RG, Venning HE, Rahman JK, Cummins CL, British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register (2011) Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 50(1):189\u2013195","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"645_CR36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RM, Reiff AO (2015) Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken) 67(5):658\u2013666","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"645_CR37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S (2017) Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: A survey of the Childhood Arthritis and Rheumatology Research Alliance. J\u00a0Rheumatol 44(3):352\u2013360","journal-title":"J Rheumatol"},{"issue":"4","key":"645_CR38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.27348","volume":"62","author":"J Kremer","year":"2010","unstructured":"Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P (2010) Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 62(4):917\u2013928","journal-title":"Arthritis Rheum"},{"issue":"1","key":"645_CR39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5114\/aoms.2018.73714","volume":"15","author":"K Ma","year":"2018","unstructured":"Ma K, Li L, Liu C, Zhou L, Zhou X (2018) Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: A\u00a0network meta-analysis. Arch Med Sci 15(1):33\u201354","journal-title":"Arch Med Sci"},{"issue":"8","key":"645_CR40","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.34458","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG et\u00a0al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(8):2773\u20132780. \nhttps:\/\/doi.org\/10.1002\/art.34458","journal-title":"Arthritis Rheum"},{"issue":"5","key":"645_CR41","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","volume":"65","author":"T Beukelman","year":"2013","unstructured":"Beukelman T, Xie F, Baddley JW et\u00a0al (2013) Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 65(5):1384\u20131389","journal-title":"Arthritis Rheum"},{"issue":"1","key":"645_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","volume":"18","author":"T Beukelman","year":"2016","unstructured":"Beukelman T, Xie F, Baddley JW et\u00a0al (2016) The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 18(1):210. \nhttps:\/\/doi.org\/10.1186\/s13075-016-1109-8","journal-title":"Arthritis Res Ther"},{"key":"645_CR43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.40493","volume":"70","author":"JM Kremer","year":"2018","unstructured":"Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M (2018) Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab. Arthritis Rheumatol 70:1200\u20131208","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"645_CR44","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/annrheumdis-2016-210561","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF et\u00a0al (2017) Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis 76(7):1279\u20131284. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2016-210561","journal-title":"Ann Rheum Dis"},{"key":"645_CR45","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"P Diak","year":"2010","unstructured":"Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A (2010) Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum 62:2517\u20132524","journal-title":"Arthritis Rheum"},{"issue":"9","key":"645_CR46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","volume":"64","author":"BL Nordstrom","year":"2012","unstructured":"Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ (2012) Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken) 64(9):1357\u20131364","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"645_CR47","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","volume":"62","author":"JF Simard","year":"2010","unstructured":"Simard JF, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum 62(12):3776\u20133782","journal-title":"Arthritis Rheum"},{"issue":"4","key":"645_CR48","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR et\u00a0al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263\u20131271","journal-title":"Arthritis Rheum"},{"issue":"5","key":"645_CR49","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56(5):1433\u20131439","journal-title":"Arthritis Rheum"},{"key":"645_CR50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","volume":"77","author":"T Beukelman","year":"2018","unstructured":"Beukelman T, Xie F, Chen L et\u00a0al (2018) Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis 77:1012\u20131016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"645_CR51","first-page":"1113","volume":"34","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K (2016) Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER registry. Clin Exp Rheumatol 34(6):1113\u20131120","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"645_CR52","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","volume":"352","author":"E Silverman","year":"2005","unstructured":"Silverman E, Mouy R, Spiegel L et\u00a0al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N\u00a0Engl J Med 352(16):1655\u20131666","journal-title":"N Engl J Med"},{"key":"645_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ (2014) Treatment of juvenile idiopathic arthritis: A revolution in care. Pediatr Rheumatol Online\u00a0J 12:13. \nhttps:\/\/doi.org\/10.1186\/1546-0096-12-13","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0645-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0645-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0645-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:21:42Z","timestamp":1589239302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0645-4"}},"subtitle":["Vergleich von Mono- und Kombinationstherapie mit synthetischen DMARDs","A comparison of mono- and combination therapy with synthetic DMARDs"],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0645-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"13 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Klein gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}